SLC5A2 and chronic kidney disease: Of these, 1 trial included 3 different doses of SGLT2 inhibitors,[23] 3 trials contained 2 different doses of SGLT2 inhibitors[20–22] and 4 trials contained only 1 dose of SGLT2 inhibitor.[16,17,19,25] One trial included groups in different stages of CKD.[24] We included these results in pooled analysis and regarded them as different comparisons.